- Last Close 18.55
- Sector Healthcare
- Industry Drug Manufacturers - Specialty & Generic
- Investment Style Small Blend
- Day Range — – —
- Year Range — – —
- Market Cap —
- Volume / Avg 800.0 / 800.0
- Price / Sales 1.40
- Price / Book 1.04
- Forward Div Yield 3.66%
- Trailing Div Yield —
Morningstar‘s Stock Analysis KYRNF
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile KYRNF
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
Tokyo, 101-8311, JPN
Competitors & Peers KYRNF
Morningstar does not cover competitors or peers for this firm.
FAQs for Kyorin Pharmaceutical Co Ltd Stock
Yes. KYRNF has a forward dividend yield of 0.02%.
KYRNF’s full dividends and stock split history
on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
KYRNF’s stock style is Small Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
KYRNF’s price/sales is 1.40.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.
KYRNF’s price/forward earnings is 12.48.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.
KYRNF’s price/book is 1.04.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.
See KYRNF’s valuation ratios compared to the Market Index.
KYRNF’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare KYRNF’s historical performance against its industry peers and the overall market.